RxDoctor Payments Data

Laura Degeorge, APRN

Family · Trumbull, CTNPI 1003123985

Payments from drug & device makers

$1,991in general payments, 2019–2025

Across 85 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$500
  • Merck$328
  • Boston Scientific$305
  • Boehringer Ingelheim$194
  • Pfizer$143
  • Kiniksa Pharmaceuticals International, PLC$112
  • plus $409 from 9 others

What the payments were for

  • Food & beverage$1,991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,991 in reported general payments places this provider in the 80th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,358
Medicare patients
178
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban965$1,175,022
XareltoRivaroxaban211$263,277
EntrestoSacubitril/Valsartan183$208,533
Repatha SureclickEvolocumab115$108,078
JardianceEmpagliflozin75$90,006
MultaqDronedarone Hcl37$66,692
Praluent PenAlirocumab35$27,110
Metoprolol Succinate1,055$14,021
LivaloPitavastatin Calcium16$11,908
Atorvastatin Calcium984$10,303
Rosuvastatin Calcium772$10,283
Nebivolol Hcl71$6,174
VascepaIcosapent Ethyl12$5,954
Ranolazine ErRanolazine47$5,218
Valsartan189$4,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$143$1,175,022965 claims
Johnson & JohnsonXarelto$37$263,277211 claims
NovartisEntresto$50$208,533183 claims
Boehringer IngelheimJardiance$194$90,00675 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,596 family providers in Connecticut.

Other family in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →